PT - JOURNAL ARTICLE AU - Pagadala, Meghana S. AU - Lynch, Julie AU - Karunamuni, Roshan AU - Alba, Patrick R. AU - Lee, Kyung Min AU - Agiri, Fatai Y. AU - Anglin, Tori AU - Carter, Hannah AU - Gaziano, J. Michael AU - Jasuja, Guneet Kaur AU - Deka, Rishi AU - Rose, Brent S. AU - Panizzon, Matthew S. AU - Hauger, Richard L. AU - Seibert, Tyler M. TI - Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort AID - 10.1101/2021.09.24.21264093 DP - 2022 Jan 01 TA - medRxiv PG - 2021.09.24.21264093 4099 - http://medrxiv.org/content/early/2022/02/16/2021.09.24.21264093.short 4100 - http://medrxiv.org/content/early/2022/02/16/2021.09.24.21264093.full AB - Background Genetic scores may provide an objective measure of a man’s risk of dying from prostate cancer and thus inform screening decisions, especially in men of African ancestry, who have a higher average risk of prostate cancer death but are often treated as a homogeneous group.Objective Determine whether a polygenic hazard score based on 290 genetic variants (PHS290) is associated with risk of fatal or metastatic prostate cancer in a diverse population.Design, Setting, and Participants Retrospective analysis of Million Veteran Program (MVP), a national, population-based cohort study of United States military veterans conducted 2011-2021.Exposure(s) Genotype data to calculate the genetic score, PHS290. Family history of prostate cancer and ancestry group (European, African, Hispanic, or Asian) were also studied.Outcome Measurements and Statistical Analysis Primary outcome: age at death from prostate cancer. Key secondary outcome: age at diagnosis of prostate cancer metastases. Statistical analysis: Cox proportional hazards.Results 582,515 MVP participants. Median age at last follow-up: 69 years. PHS290 was associated with fatal prostate cancer in the full cohort and for each ancestry group (p<10-16). Comparing men in the highest 20% of PHS290 to those in the lowest 20%, the hazard ratio for death from prostate cancer was 4.41 [95% CI: 3.9-5.02]. Corresponding hazard ratios for European, African, Hispanic, and Asian subsets were 4.26 [3.66-4.9], 2.4 [1.77-3.23], 4.72 [2.68-8.87], and 10.46 [2.01-101.0]. When accounting for family history and ancestry group, PHS290 remained a strong independent predictor of fatal prostate cancer. PHS290 was also associated with metastasis.Conclusions PHS290 stratified US veterans of diverse ancestry for lifetime risk of metastatic or fatal prostate cancer. Predicting genetic risk of lethal prostate cancer with PHS290 might inform individualized decisions about prostate cancer screening.Patient Summary In a large, diverse population (including over 100,000 African Americans), we evaluated whether a genetic score (PHS290) was associated with a man’s risk of fatal or metastatic prostate cancer. We conclude that men with a high PHS290 genetic score, independent of ancestry or family history, are more likely to die of prostate cancer. This information might be useful to guide which men might benefit from screening for prostate cancer.Competing Interest StatementTMS reports honoraria from Varian Medical Systems and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board; he has received in-kind research support from GE Healthcare via a research agreement with the University of California San Diego. These companies might potentially benefit from the research results. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.Funding StatementThis research used data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration. This research was supported by the Million Veteran Program MVP022 award # I01 CX001727 (PI: Richard L. Hauger MD). This publication does not represent the views of the Department of Veterans Affairs or the United States Government. Dr. Hauger was additionally funded by the VISN-22 VA Center of Excellence for Stress and Mental Health (CESAMH) and National Institute of Aging RO1 grant AG050595 (The VETSA Longitudinal Twin Study of Cognition and Aging VETSA 4). This research was supported by VA MVP022. Meghana S. Pagadala was supported by the National Institutes of Health (#1F30CA247168, #T32CA067754). Tyler Seibert and Roshan Karunamuni were supported by the National Institutes of Health (NIH/NIBIB #K08EB026503), the Prostate Cancer Foundation, and the University of California (#C21CR2060).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:VA Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests regarding data access may be directed to MVPLOI{at}va.gov